Celgene Corporation announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a phase-III, randomized, double-blind, multi-centre clinical study led by the Cancer and Leukaemia Group B (CALGB). The investigational study evaluated Revlimid compared to placebo in multiple myeloma patients following autologous stem cell transplant, and the independent Data and Safety Monitoring Board reported that the trial had met its primary endpoint of a statistically significant improvement in time to disease progression. The study was sponsored by the NCI under a Clinical Trials Agreement with Celgene.

Further results from the study will be presented in a peer-reviewed setting in 2010.

Revlimid is an IMiDs compound. Revlimid and other IMiDs continue to be evaluated in over 100 clinical trials.

Celgene Corporation is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation.